Pfizer drug company reported its late-stage patient study found an extended-release version of its pain killer Lyrica worked better than placebo pill but did not last much longer, according to USA Today. The study is one of three late-stage patient tests by Pfizer to get approval of Lyrica for other use, such as long-term daily use for limiting fibromyalgia pain. A shorter-acting version of the drug to be taken twice daily is approved in 120 countries for treating pain flare-ups.
After 12 weeks, 54 percent of the 121 patients given Lyrica and 71 percent of placebo patients had much, if not all, of their pain return. Lyrica stopped providing significant pain relief within 58 days, versus 22 days for placebo pills.
More Articles on Pain Management:
Prescription Drug Abuse an 'Epidemic'
National Pain Institute to Offer 20 New Pain Management Treatments
Kimberly-Clark Hosts Live Streaming Cadaver Course on Pain Management
After 12 weeks, 54 percent of the 121 patients given Lyrica and 71 percent of placebo patients had much, if not all, of their pain return. Lyrica stopped providing significant pain relief within 58 days, versus 22 days for placebo pills.
More Articles on Pain Management:
Prescription Drug Abuse an 'Epidemic'
National Pain Institute to Offer 20 New Pain Management Treatments
Kimberly-Clark Hosts Live Streaming Cadaver Course on Pain Management